"We don't reinvent the wheel.
We repair the broken spokes."
– Hal Crow, Chairman
Tosk was founded to discover and develop new drugs for cancer and other conditions using non-mammalian animal species as models for human diseases. We call this approach Optimizing Marketed Drugs™ or OMD™. These efforts evolved into two proprietary drug discovery platforms that use the common fruit fly (Drosophila melanogaster) as a tool to discover new drugs.
The Company uses one application of this technology, known as the Side Effect Fly, to discover agents that reduce or eliminate the adverse effects of existing drugs. The first applications of the technology are for the widely used chemotherapeutics, methotrexate, doxorubicin, and cisplatin. Tosk's most advanced drug, TK-90 for mucositis side effect reduction, has recently entered the second phase of human clinical testing.
A second application, known at the Genetically Modified Fly, uses Drosophila into which we implant human cancer genes. The first application of this technology targets the human kRAS oncogene, which limits the effectiveness of an important class of cancer drugs and promotes tumor growth in certain cancers.